University of Minnesota Pioneers Less Invasive Treatments for Glioblastoma
In a significant advancement for brain cancer treatment, the University of Minnesota's Department of Neurosurgery is conducting a series of clinical trials aimed at combating glioblastoma, the most aggressive form of brain cancer. These trials include innovative approaches such as laser ablation, engineered viruses, and a drug that helps identify tumor locations, offering new hope to patients.
Laser Ablation: A Less Invasive Alternative
One of the treatments under trial is laser ablation, a method that uses a laser to heat and kill cancer cells. This technique is less invasive than traditional brain surgeries, allowing for a shorter recovery time. Brian Braun, a patient who underwent this treatment, reported a positive experience, highlighting a quicker recovery and improved quality of life compared to more invasive procedures.
Engineered Viruses: A Novel Approach to Cancer Treatment
The University is also exploring the use of engineered viruses to fight glioblastoma. One method involves injecting a virus designed to combat the cancer into the patient's brain post-surgery. The patient then takes a drug that targets only the areas affected by the virus. This trial is in its final stages, with results expected in the coming years.
Enhancing Tumor Identification with 5-ALA
Another promising trial involves the drug 5-ALA, which aids surgeons in identifying tumor locations using special lighting. This is particularly useful as distinguishing tumor tissue from healthy brain matter can be challenging. This trial is set to begin in a few months, offering another tool in the fight against glioblastoma.
The Urgency of Glioblastoma Treatment
Glioblastoma is a devastating disease, with an estimated 24,000 new cases in 2018 alone. Without treatment, the prognosis is grim, with most patients surviving only three months. Even with chemotherapy, survival rates are low, emphasizing the importance of these clinical trials in developing more effective treatments.
Dr. Clark Chen, chair of the Department of Neurosurgery, underscores the significance of these advancements, stating, "These advances are kind of space-age." By directly targeting cancer cells and minimizing the invasiveness of treatments, the University of Minnesota's clinical trials represent a beacon of hope for glioblastoma patients worldwide.
